Larimar Therapeutics is a clinical-stage biotech firm that leverages its unique cell-penetrating peptide tech to develop remedies for rare diseases. One of the company's current projects is CTI-1601, a drug undergoing Phase 1 clinical trials for the treatment of Friedreich's ataxia, a rare genetic ailment that is fatal and progressive in nature. Larimar Therapeutics is headquartered in Bala Cynwyd, Pennsylvania.